IBIO vs PATH · rev $100.0K vs P/E 19, rev $1.61B
iBio, Inc. Common Stock (IBIO) versus Uipath Inc (PATH) — a side-by-side from cached financials, not a winner call.
iBio, Inc. Common Stock (IBIO) is a biotechnology company listed on US.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Latest reported IBIO revenue for 2026-06-30 was $100.0K. Net income was -$32.8M. Revenue was down 75.0% from 2025-06-30 to 2026-06-30. IBIO currently screens at market cap $13.4M.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
IBIO currently screens at market cap $13.4M. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Not investment advice. Open the IBIO and PATH stock pages for the full models.
Not investment advice.